药物诱发噬血细胞性淋巴组织细胞增多症的诊断及治疗

王宇翔; 郭涛

doi:10.13201/j.issn.1004-2806.2023.01.004

药物诱发噬血细胞性淋巴组织细胞增多症的诊断及治疗

王宇翔¹,
郭涛^1, ,

- 华中科技大学同济医学院附属协和医院血液内科(武汉，430022)
基金项目:
国家自然科学基金面上项目(No：81974008)

详细信息

作者简介:
郭涛，华中科技大学同济医学院附属协和医院血液科主任医师、博士生导师。担任中国医师协会血液科医师分会委员，海峡两岸医药卫生交流协会血液病学专业委员会副主任委员，武汉血液学会主任委员，中国研究型医院协会生物治疗学组常务委员。《临床血液学杂志》《血栓与止血学》《国际输血及血液学杂志》及《临床急诊杂志》编委。湖北省噬血细胞综合征专家联盟理事长

通讯作者: 郭涛，E-mail：guotao1968@163.com

中图分类号: R55

收稿日期: 2022-12-02

刊出日期: 2023-01-01

Diagnosis and treatment of drugs-induced hemophagocytic lymphohistiocytosis

WANG Yuxiang¹,
GUO Tao^1, ,

- Department of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China

More Information

Corresponding author: GUO Tao, E-mail: guotao1968@163.com

Received Date: 02 December 2022

Publish Date: 01 January 2023

摘要

摘要: 噬血细胞性淋巴组织细胞增多症又称噬血细胞综合征，是一种威胁生命的严重疾病，通常伴有发热、血细胞减少、肝脾肿大等临床特征。近年来，随着新的治疗药物的临床使用，尤其是嵌合抗原受体T细胞免疫疗法、免疫检查点抑制剂等，药物诱发噬血细胞综合征逐渐引起临床医生的重视。文章总结了几类药物诱发噬血细胞综合征的诊断及治疗，包括免疫治疗药物、化疗药物、抗生素等。其中，嵌合抗原受体T细胞免疫疗法诱发噬血细胞综合征具有较明确的诊疗标准，其他药物诱发噬血细胞综合征的诊疗标准仍有待完善。
- 药物诱发噬血细胞性淋巴组织细胞增多症 /
- 免疫治疗药物 /
- 化疗药物 /
- 抗生素
Abstract: Hemophagocytic lymphohistiocytosis is a life-threatening disease, characterized by pyrexia, hypocytosis and hepatosplenomegaly. In recent years, with the widespread use of new drugs, especially chimeric antigen receptor T-cell immunotherapy and immune checkpoint inhibitors, drugs-induced hemophagocytic lymphohistiocytosis gradually comes to the spotlight. It summarizes the diagnosis and treatment of hemophagocytic lymphohistiocytosis induced by kinds of drugs, such as immunotherapy drugs, chemotherapy drugs and antibiotics. Hemophagocytic lymphohistiocytosis induced by chimeric antigen receptor T-cell immunotherapy and immune checkpoint inhibitors has more specific diagnosis and treatment criteria, while diagnosis and treatment criteria of other drugs-induced hemophagocytic lymphohistiocytosis need to be further improved.
- drugs-induced hemophagocytic lymphohistiocytosis /
- immunotherapy drugs /
- chemotherapy drugs /
- antibiotics

HTML全文

参考文献(42)

[1]	Al-Samkari H, Berliner N. Hemophagocytic Lymphohistiocytosis[J]. Annu Rev Pathol, 2018, 13: 27-49. doi: 10.1146/annurev-pathol-020117-043625
[2]	La Rosée P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults[J]. Blood, 2019, 133(23): 2465-2477. doi: 10.1182/blood.2018894618
[3]	Wei J, Guo Y, Wang Y, et al. Clinical development of CAR T cell therapy in China: 2020 update[J]. Cell Mol Immunol, 2021, 18(4): 792-804. doi: 10.1038/s41423-020-00555-x
[4]	Hu Y, Wu Z, Luo Y, et al. Potent Anti-leukemia Activities of Chimeric Antigen Receptor-Modified T Cells against CD19 in Chinese Patients with Relapsed/Refractory Acute Lymphocytic Leukemia[J]. Clin Cancer Res, 2017, 23(13): 3297-3306. doi: 10.1158/1078-0432.CCR-16-1799
[5]	Giavridis T, Van Der Stegen SJC, Eyquem J, et al. CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade[J]. Nat Med, 2018, 24(6): 731-738. doi: 10.1038/s41591-018-0041-7
[6]	Vick EJ, Patel K, Prouet P, et al. Proliferation through activation: hemophagocytic lymphohistiocytosis in hematologic malignancy[J]. Blood Adv, 2017, 1(12): 779-791. doi: 10.1182/bloodadvances.2017005561
[7]	Lee DW, Santomasso BD, Locke FL, et al. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells[J]. Biol Blood Marrow Transplant, 2019, 25(4): 625-638. doi: 10.1016/j.bbmt.2018.12.758
[8]	Prencipe G, Caiello I, Pascarella A, et al. Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome[J]. J Allergy Clin Immunol, 2018, 141(4): 1439-1449. doi: 10.1016/j.jaci.2017.07.021
[9]	Norelli M, Camisa B, Barbiera G, et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells[J]. Nat Med, 2018, 24(6): 739-748. doi: 10.1038/s41591-018-0036-4
[10]	Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells[J]. Hepatology, 2009, 49(3): 887-900.
[11]	Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells[J]. Blood, 2021, 138(24): 2469-2484. doi: 10.1182/blood.2021011898
[12]	Michot JM, Lazarovici J, Tieu A, et al. Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?[J]. Eur J Cancer, 2019, 122: 72-90. doi: 10.1016/j.ejca.2019.07.014
[13]	Zhuang J, Du J, Guo X, et al. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events[J]. Thorac Cancer, 2020, 11(3): 799-804. doi: 10.1111/1759-7714.13281
[14]	Postow MA, Sidlow R, Hellmann MD. Immune-Related Adverse Events Associated with Immune Checkpoint Blockade[J]. N Engl J Med, 2018, 378(2): 158-168. doi: 10.1056/NEJMra1703481
[15]	Teachey DT, Rheingold SR, Maude SL, et al. Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy[J]. Blood, 2013, 121(26): 5154-5157. doi: 10.1182/blood-2013-02-485623
[16]	Jawed SI, Busam K, Wang X, et al. Cutaneous hemophagocytosis after alemtuzumab injection in a patient with Sézary syndrome[J]. JAMA Dermatol, 2014, 150(9): 1021-1023. doi: 10.1001/jamadermatol.2013.10615
[17]	Ambinder AJ, Hambley B, Shanbhag S, et al. Ibrutinib-associated hemophagocytic lymphohistiocytosis: A case series from Johns Hopkins[J]. Am J Hematol, 2019, 94(11): E296-E299.
[18]	Jayakody Arachchillage D, Hurst E, Carey P, et al. Haemophagocytic lymphohistiocytosis following fludarabine/cyclophosphamide chemotherapy for chronic lymphocytic leukaemia[J]. Br J Haematol, 2014, 166(1): 142-145. doi: 10.1111/bjh.12822
[19]	Runge E, Kou CJ, Rendo M, et al. Lenalidomide-Associated Hemophagocytic Lymphohistiocytosis With Plasma Cell Phagocytosis[J]. Cureus, 2021, 13(4): e14409.
[20]	Picard M, Fernandez MI, Des Roches A, et al. Ceftazidime-induced drug reaction with eosinophilia and systemic symptoms(DRESS)complicated by hemophagocytic lymphohistiocytosis[J]. J Allergy Clin Immunol Pract, 2013, 1(4): 409-412. doi: 10.1016/j.jaip.2013.04.001
[21]	Kim T, Kulick CG, Kortepeter CM, et al. Hemophagocytic lymphohistiocytosis associated with the use of lamotrigine[J]. Neurology, 2019, 92(21): e2401-e2405. doi: 10.1212/WNL.0000000000007517
[22]	Kirik S, Gunes H, Yurttutan S, et al. Hemophagocytic lymphohistiocytosis associated with oxcarbazepine[J]. Turk J Pediatr, 2019, 61(2): 297-300. doi: 10.24953/turkjped.2019.02.025
[23]	Liu Q, Zhao S, Chen W. Clinical features, treatment outcomes and prognostic factors of allopurinol-induced DRESS in 52 patients[J]. J Clin Pharm Ther, 2022, 47(9): 1368-1378. doi: 10.1111/jcpt.13667
[24]	Noseda R, Bertoli R, Muller L, et al. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports[J]. J Immunother Cancer, 2019, 7(1): 117. doi: 10.1186/s40425-019-0598-9
[25]	Henter JI, Horne A, Aricó M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis[J]. Pediatr Blood Cancer, 2007, 48(2): 124-131. doi: 10.1002/pbc.21039
[26]	Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome[J]. Arthritis Rheumatol, 2014, 66(9): 2613-2620. doi: 10.1002/art.38690
[27]	Neelapu SS, Tummala S, Kebriaei P, et al. Chimeric antigen receptor T-cell therapy-assessment and management of toxicities[J]. Nat Rev Clin Oncol, 2018, 15(1): 47-62. doi: 10.1038/nrclinonc.2017.148
[28]	Shah NN, Highfill SL, Shalabi H, et al. CD4/CD8 T-Cell Selection Affects Chimeric Antigen Receptor(CAR)T-Cell Potency and Toxicity: Updated Results From a Phase Ⅰ Anti-CD22 CAR T-Cell Trial[J]. J Clin Oncol, 2020, 38(17): 1938-1950. doi: 10.1200/JCO.19.03279
[29]	Lehmberg K, Nichols KE, Henter JI, et al. Consensus recommendations for the diagnosis and management of hemophagocytic lymphohistiocytosis associated with malignancies[J]. Haematologica, 2015, 100(8): 997-1004.
[30]	Santomasso BD, Nastoupil LJ, Adkins S, et al. Management of Immune-Related Adverse Events in Patients Treated With Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline[J]. J Clin Oncol, 2021, 39(35): 3978-3992. doi: 10.1200/JCO.21.01992
[31]	Major A, Collins J, Craney C, et al. Management of hemophagocytic lymphohistiocytosis(HLH)associated with chimeric antigen receptor T-cell(CAR-T)therapy using anti-cytokine therapy: an illustrative case and review of the literature[J]. Leuk Lymphoma, 2021, 62(7): 1765-1769. doi: 10.1080/10428194.2021.1881507
[32]	Strati P, Ahmed S, Kebriaei P, et al. Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma[J]. Blood Adv, 2020, 4(13): 3123-3127. doi: 10.1182/bloodadvances.2020002328
[33]	Wohlfarth P, Agis H, Gualdoni GA, et al. Interleukin 1 Receptor Antagonist Anakinra, Intravenous Immunoglobulin, and Corticosteroids in the Management of Critically Ill Adult Patients With Hemophagocytic Lymphohistiocytosis[J]. J Intensive Care Med, 2019, 34(9): 723-731. doi: 10.1177/0885066617711386
[34]	Miao L, Zhang Z, Ren Z, et al. Reactions Related to CAR-T Cell Therapy[J]. Front Immunol, 2021, 12: 663201. doi: 10.3389/fimmu.2021.663201
[35]	Wang H, Liu H, Li J, et al. Cytokine nanosponges suppressing overactive macrophages and dampening systematic cytokine storm for the treatment of hemophagocytic lymphohistiocytosis[J]. Bioact Mater, 2023, 21: 531-546. doi: 10.1016/j.bioactmat.2022.09.012
[36]	Dupré A, Michot JM, Schoeffler A, et al. Haemophagocytic lymphohistiocytosis associated with immune checkpoint inhibitors: a descriptive case study and literature review[J]. Br J Haematol, 2020, 189(5): 985-992. doi: 10.1111/bjh.16630
[37]	Miyabayashi H, Kumaki S, Sato A, et al. Onset of Hemophagocytic Lymphohistiocytosis during Piperacillin-Tazobactam Therapy in Three Children with Acute Focal Bacterial Nephritis[J]. Tohoku J Exp Med, 2018, 245(1): 55-59. doi: 10.1620/tjem.245.55
[38]	Pope EI, Au H, Levy DM, et al. Case report: Drug reaction with eosinophilia and systemic symptoms(DRESS)-induced hemophagocytic disorder[J]. Front Pharmacol, 2022, 13: 1023522. doi: 10.3389/fphar.2022.1023522
[39]	Lambotte O, Costedoat-Chalumeau N, Amoura Z, et al. Drug-induced hemophagocytosis[J]. Am J Med, 2002, 112(7): 592-593. doi: 10.1016/S0002-9343(02)01035-5
[40]	Jordan MB, Allen CE, Weitzman S, et al. How I treat hemophagocytic lymphohistiocytosis[J]. Blood, 2011, 118(15): 4041-4052. doi: 10.1182/blood-2011-03-278127
[41]	康晶, 王诗轩, 李菲. 噬血细胞综合征出凝血功能障碍的发生机制及其临床特点和治疗的研究进展[J]. 中国实验血液学杂志, 2022, 30(3): 959-964. doi: 10.19746/j.cnki.issn1009-2137.2022.03.048
[42]	Hundal J, Bowers D, Gadela NV, et al. Rare Case of Refractory Hypoxia and Severe Multiorgan Failure from Secondary Lymphohistiocytosis Successfully Bridged to Treatment with Extracorporeal Membrane Oxygenation Support[J]. Indian J Crit Care Med, 2022, 26(8): 970-973. doi: 10.5005/jp-journals-10071-24284